Who
Donald A. Bergstrom
President, R&D
Company insider
Files Form 4 as: President, R&D, Relay Therapeutics; Director, Fusion Pharmaceuticals; Chief Medical Officer, Mersana Therapeutics.
In numbers
- Trades disclosed
- 129
- Buys
- 0
- Sells
- 61
- Bought
- $0
- Sold
- $14.3M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 2 Feb 2018
- Last trade
- 8 Sep 2026
- Last filed
- 9 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Sep 2026filed 9 Sep 2026 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Sold | $162K8,530 at $18.97 | filing |
| 8 Sep 2026filed 9 Sep 2026 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Sold | $162K8,530 at $18.97 | filing |
| 28 Jul 2026filed 30 Jul 2026 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Sold | $42K2,237 at $18.61 | filing |
| 28 Jul 2026filed 30 Jul 2026 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Sold | $42K2,237 at $18.61 | filing |
| 6 Jul 2026filed 8 Jul 2026 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Sold | $162K8,660 at $18.71 | filing |
| 6 Jul 2026filed 8 Jul 2026 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Sold | $162K8,660 at $18.71 | filing |
| 22 Jun 2026filed 24 Jun 2026 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Code M | $385K93,456 at $4.12 | filing |
| 22 Jun 2026filed 24 Jun 2026 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.6M93,456 at $16.94 | filing |
| 22 Jun 2026filed 24 Jun 2026 | RLAY Relay Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —93,456 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | RLAY Relay Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —93,456 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Code M | $385K93,456 at $4.12 | filing |
| 22 Jun 2026filed 24 Jun 2026 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.6M93,456 at $16.94 | filing |
| 28 Apr 2026filed 30 Apr 2026 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Sold | $22K1,490 at $14.79 | filing |
| 28 Apr 2026filed 30 Apr 2026 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Sold | $22K1,490 at $14.79 | filing |
| 28 Jan 2026filed 29 Jan 2026 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Sold | $23K2,686 at $8.45 | filing |
| 28 Jan 2026filed 29 Jan 2026 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Sold | $23K2,686 at $8.45 | filing |
| 27 Jan 2026filed 29 Jan 2026 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Sold | $144K18,895 at $7.62 | filing |
| 27 Jan 2026filed 29 Jan 2026 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Sold | $144K18,895 at $7.62 | filing |
| 13 Jan 2026filed 15 Jan 2026 | RLAY Relay Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —575,000 at $0.00 | filing |
| 13 Jan 2026filed 15 Jan 2026 | RLAY Relay Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —575,000 at $0.00 | filing |
News
Head-To-Head Comparison: Krystal Biotech (NASDAQ:KRYS) and Relay Therapeutics (NASDAQ:RLAY)RLAY · tickerreport.com · 11 Oct 2026
0 headlines in the last 90 days name Donald A. Bergstrom; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.